KNSA - Kiniksa Pharmaceuticals, Ltd.
IEX Last Trade
19.61
-0.580 -2.958%
Share volume: 10
Last Updated: Fri 27 Dec 2024 03:30:46 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-1.15%
PREVIOUS CLOSE
CHG
CHG%
$20.19
-0.58
-2.87%
Fundamental analysis
9%
Profitability
2%
Dept financing
4%
Liquidity
71%
Performance
0%
Performance
5 Days
-1.53%
1 Month
-9.53%
3 Months
-16.78%
6 Months
7.61%
1 Year
7.20%
2 Year
28.98%
Key data
Stock price
$19.61
DAY RANGE
$20.19 - $20.19
52 WEEK RANGE
$17.05 - $28.15
52 WEEK CHANGE
$11.71
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/29/2024
Company detail
CEO: Sanj K. Patel
Region: US
Website: kiniksa.com
Employees: 220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: kiniksa.com
Employees: 220
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Kiniksa Pharmaceuticals, Ltd. focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease. KPL-404 is a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation.
Recent news